Omalizumab, when combined with immunotherapy, can substantially decrease adverse allergic reaction, revealed a review paper authored by Jennifer A. Dantzer, assistant professor of pediatrics, Division of Allergy, Immunology, and Rheumatology at the Johns Hopkins School of Medicine. 

The review said that combining the 2 therapy would improve the odds of a better outcome as both immunotherapy and omalizumab have individual limiting factors such as potential adverse reactions and difficulty of administering respectively. These are eliminated in the add-on treatment. Dantzer also expressed hopes that the drug will be approved soon as an add-on therapy to allergen immunotherapy and urged clinicians to take it into consideration while treating serious asthma patients.